FPS
ZNTL icon

Fieldpoint Private Securities’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Fieldpoint Private Securities’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$25K Sell
902
-2
-0.2% -$53 0.01% 595
2022
Q1 		$42K Hold
904
– – 0.01% 637
2021
Q4 		$76K Buy
+904
New +$69.9K 0.01% 494

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Fieldpoint Private Securities's ZNTL Position: Q2 2022 in Review

Fieldpoint Private Securities reduced its Zentalis Pharmaceuticals (ZNTL) stake by 0.22% in Q2 2022, selling an estimated $53 and leaving 902 shares worth $25K. The position accounts for 0.01% of the portfolio, ranked #595.

Fieldpoint Private Securities first reported a position in ZNTL in Q4 2021 and has held it in 3 quarters since. The position peaked at $76K in Q4 2021. 122 funds tracked by Wall St. Rank hold ZNTL as of Q2 2022.

  • Fieldpoint Private Securities held 902 shares of Zentalis Pharmaceuticals worth $25K as of Q2 2022.
  • Fieldpoint Private Securities sold 2 Zentalis Pharmaceuticals shares in Q2 2022, an estimated $53.
  • Zentalis Pharmaceuticals made up 0.01% of Fieldpoint Private Securities's portfolio in Q2 2022, its #595 holding.
  • Fieldpoint Private Securities first reported a position in Zentalis Pharmaceuticals in Q4 2021 and has held it in 3 quarters since.
  • Fieldpoint Private Securities's Zentalis Pharmaceuticals position peaked at $76K in Q4 2021.
  • 122 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.